Condition category
Haematological Disorders
Date applied
07/09/2020
Date assigned
09/09/2020
Last edited
09/09/2020
Prospective/Retrospective
Prospectively registered
Overall trial status
Ongoing
Recruitment status
Not yet recruiting

Plain English Summary

Background and study aims
Sickle cell disease (SCD) is a group of inherited health conditions that affect the red blood cells. The symptoms include painful episodes called sickle cell crises, which can be very severe and last up to a week. The current understanding of SCD's full natural history and the available treatment options for patients fall far behind that of many other diseases with a similar prevalence. Patient care is impacted by limitations around the data available to their clinicians outside of infrequent contacts with treatment centres, meaning the standard of care and speed at which it can be delivered is frequently lacking.
The aim of this study is to find out whether a unified SCD digital data platform and wearable device improves patient experiences and outcomes through better monitoring of key metrics around pain crises and severe complications of the disease. These will be tracked through a combination of hospital and GP medical records, genetic information, as well as real-time data collected from the wearable devices.
By combining these into a complete digital patient profile, the aim is to provide patients and clinicians with better insight into the disease's natural history, which interventions have worked well in order to improve future treatment, and inform when a patient may be at risk of crises or severe end-organ pathologies. The work will study vital parameters collected over a long duration within a group of patients with SCD in order to determine how these relate to acute and chronic illnesses, as well as healthcare utilisation.

Who can participate?
1. Children with sickle cell disease aged 5-15, with consent from and attendance/guidance by parent or legal guardian
2. Adults with sickle cell disease aged 16 and over

What does the study involve?
No interventions or changes to medical treatment will be involved in the study, and all participants will follow the same study protocol.
The study will be conducted remotely, with patients participating in initial pre-study focus groups virtually over video call, in addition to a post-study focus group at the end of the study. The study of the technology will be ongoing, and participants will wear either their own or a study-provided smartwatch during their day-to-day lives, in order to track their vital parameters on a constant and automated basis. These will include metrics such as heart rate and activity levels. The study will also involve the collation of each participant's hospital and medical GP records alongside this live wearables collected data, within the digital platform. The participant will need only provide informed consent for this, and the study team will manage the data requests and integration.

What are the possible benefits and risks of participating?
There are no direct benefits in terms of changes to treatment or other aspects of participants' care. The results will add to the current knowledge about SCD, potential triggers of pain crises or complications, and individual treatment options. It will provide participants with a greater understanding of their daily health and medical history, including information that they may choose to share with their clinical team to help manage their disease.
No interventions or changes to medical treatment are involved in the study, and the only potential risk will be data security. This has been securely addressed by the study team in order to ensure strong cybersecurity measures, encryption and two-factor authentication needed to access the digital platform.

Where is the study run from?
London North West University Healthcare NHS Trust (UK)

When is the study starting and how long is it expected to run for?
July 2020 to May 2022

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
1. Mr Orlando Agrippa
orlando@draperanddash.com
2. Dr Kofi Anie MBE
kofi.anie@nhs.net

Trial website

Contact information

Type

Public

Primary contact

Dr Kim Summers

ORCID ID

https://orcid.org/0000-0002-1351-3732

Contact details

Level 39
One Canada Square
Canary Wharf
London
E14 5AB
United Kingdom
+44 (0)7480149536
kim@draperanddash.com

Type

Scientific

Additional contact

Dr Kim Summers

ORCID ID

https://orcid.org/0000-0002-1351-3732

Contact details

Level 39
One Canada Square
Canary Wharf
London
E14 5AB
United Kingdom
+44 (0)7480149536
kim@draperanddash.com

Additional identifiers

EudraCT number

Nil known

ClinicalTrials.gov number

Nil known

Protocol/serial number

IRAS 288780

Study information

Scientific title

Digital sickle cell – evaluating live evidence for vaso-occlusive crisis and end-organ damage intervention & prevention: benefits of implementing a unified digital sickle cell disease data platform, including real-time wearable device data, in disease management, patient experience, and clinical outcomes

Acronym

DiSC-ELEVEN

Study hypothesis

To determine the benefits of incorporating a unified digital data platform, in-depth digital patient profile and wearable device into standard care for sickle cell disease - collating historical patient data, a full genetic background, and live patient data - to real-world patient experiences and clinical outcomes.

Ethics approval

Submission pending

Study design

Multicentre observational pilot/feasibility study

Primary study design

Observational

Secondary study design

Cohort study

Trial setting

Home

Trial type

Other

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Sickle cell disease

Intervention

The study will be an observational trial, revolving around the use of a mobile app by participants in order to provide initial consent to participate and share their medical records with the study, key details, and link a wearable smartwatch.

The trial of the technology will be ongoing for 12 months, and participants will wear either their own or a study-provided smartwatch during their day-to-day lives, in order to track their vital parameters on a constant and automated basis. These will include metrics such as heart rate and activity levels.

The study will also involve the collation of each participant's hospital and medical GP records alongside this live wearables collected data, within the digital platform. The participant will need only provide informed consent for this, and the study team will manage the data requests and integration.

The digital data platform will unify information from multiple sources in order to provide a full patient profile that can be accessed by both patients and their clinicians. No further interventions will be involved, patients only required to wear their smartwatch on a daily basis in order for the device to collect key health metrics on an automated basis. The study will be conducted remotely, patients participating in initial pre-study focus groups virtually, over video call, in addition to a post-study focus group at the end of the trial.

Intervention type

Device

Phase

Not Applicable

Drug names

Primary outcome measure

1. Recruitment rate recorded as the number of eligible participants who consent to participate in the study by 3 months
2. Attrition rate recorded as the number of participants who consent to participate that remain in the study until the end of the follow-up period at 13 months

Secondary outcome measures

There are no secondary outcome measures

Overall trial start date

01/07/2020

Overall trial end date

22/05/2022

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Children with sickle cell disease of any phenotype aged 5-15 years of age, with consent from and attendance/guidance by parent or legal guardian
2. Adults with sickle cell disease of any phenotype aged 16 years and over
3. Able and willing to sign written informed consent
4. Interest in participating in the study
5. Known history/diagnosis of sickle cell disease

Participant type

Patient

Age group

Mixed

Gender

Both

Target number of participants

300

Participant exclusion criteria

1. Incapacity to provide informed written consent
2. Known allergic reaction to any materials in wearable device

Recruitment start date

01/10/2020

Recruitment end date

15/12/2020

Locations

Countries of recruitment

United Kingdom

Trial participating centre

London North West University Healthcare NHS Trust
Haematology and Sickle Cell Centre Central Middlesex Hospital Acton Lane
London
NW10 7NS
United Kingdom

Trial participating centre

Barts Health NHS Trust
Pathology and Pharmacy Building 80 Newark Street
London
E1 2ES
United Kingdom

Sponsor information

Organisation

Eleven

Sponsor details

Level 39
One Canada Square
Canary Wharf
London
E14 5AB
United Kingdom
+44 (0)7784288499
orlando@draperanddash.com

Sponsor type

Other

Website

Funders

Funder type

Other

Funder name

Investigator initiated and funded

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal, as well as a patient-friendly report of key findings and insights at a de-identified level provided to study participants.

IPD sharing statement
The researchers do not plan to share patient-level/raw data, as they anticipate some participants may wish to continue using the digital platform post-trial as part of their disease management. De-identified, cohort level data will be made available upon request by clinicians, researchers who provide a methodologically sound proposal, or those developing novel therapeutic options who may require the real-world evidence base generated by the study. These proposals should be directed to orlando@draperanddash.com, and will include a data access agreement. Links to the data will be provided upon request.

Intention to publish date

22/05/2023

Participant level data

Other

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

09/09/2020: Trial's existence confirmed by Health Research Authority.